Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study)
Richardson AJ, Burton JR, Sewell RP, Spreckelsen TF, Montgomery P
PloS one · 104 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Waterloo Foundation
- Universidad u hospital
- University of Oxford
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2012-09-06 · PLoS One · vol. 7 · número 9 · pág. e43909
- Editorial
- Public Library of Science
- Citado
- 169 citas · más que el 99% de estudios similares · 15.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 28 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Child Nutrition and Water Access · Aquaculture Nutrition and Growth
- Palabras clave
- docosahexaenoic acid, omega-3 fatty acids, dietary supplementation, reading achievement, working memory, child behavior, ADHD symptoms, algal oil, low-achieving children
- MeSH
- humans, docosahexaenoic acids, treatment outcome, follow-up studies, double-blind method, behavior, parents, cognition, memory, short-term, demography, faculty, reading, child, female, male, medication adherence
5 autores
- Alex J. Richardson🇬🇧 · autor de correspondenciaUniversity of Oxford
- Jennifer Burton🇬🇧University of Oxford
- Richard P. Sewell🇬🇧University of Oxford
- Thees F. Spreckelsen🇬🇧University of Oxford
- Paul Montgomery🇬🇧University of Oxford
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Omega-3 fatty acids are dietary essentials, and the current low intakes in most modern developed countries are believed to contribute to a wide variety of physical and mental health problems. Evidence from clinical trials indicates that dietary supplementation with long-chain omega-3 may improve child behavior and learning, although most previous trials have involved children with neurodevelopmental disorders such as attention-deficit/hyperactivity disorder (ADHD) or developmental coordination disorder (DCD). Here we investigated whether such benefits might extend to the general child population.
Objectives
To determine the effects of dietary supplementation with the long-chain omega-3 docosahexaenoic acid (DHA) on the reading, working memory, and behavior of healthy schoolchildren.
Design
Parallel group, fixed-dose, randomized, double-blind, placebo-controlled trial (RCT).
Setting
Mainstream primary schools in Oxfordshire, UK (n = 74).
Participants
Healthy children aged 7-9 years initially underperforming in reading (≤ 33(rd) centile). 1376 invited, 362 met study criteria.
Intervention
600 mg/day DHA (from algal oil), or taste/color matched corn/soybean oil placebo.
Main outcome measures
Age-standardized measures of reading, working memory, and parent- and teacher-rated behavior.
Results
ITT analyses showed no effect of DHA on reading in the full sample, but significant effects in the pre-planned subgroup of 224 children whose initial reading performance was ≤ 20(th) centile (the target population in our original study design). Parent-rated behavior problems (ADHD-type symptoms) were significantly reduced by active treatment, but little or no effects were seen for either teacher-rated behaviour or working memory.
Conclusions
DHA supplementation appears to offer a safe and effective way to improve reading and behavior in healthy but underperforming children from mainstream schools. Replication studies are clearly warranted, as such children are known to be at risk of low educational and occupational outcomes in later life.
Trial registration
ClinicalTrials.gov NCT01066182 and Controlled-Trials.com ISRCTN99771026.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.